Benazeprilat

Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage^[1][2][3]. In Vivo: Benazeprilat (10 mg/kg, intravenous injection) and amlodipine (0.5 mg/kg, intravenous injection) in combination produce great hypotensive effect^[2].
Benazepril (0.7 mg/kg, oral) markedly influences the dynamics of systemic RAAS peptides, resulting in a substantial decrease in AII and ALD while increasing PRA and AI^[3].